John J. Miller

Pharmacogenomics at the 2024 APA Annual Meeting.

SPECIAL REPORT: ADVANCES IN PSYCHIATRY We are at the halfway point of the year, and psychiatry continues to be exciting, with advances in the field, potential new treatments on the horizon, and great insights from leaders in the field. This special report helps to keep that conversation and momentum going by covering highlights from the 2024 American Psychiatric Association’s Annual Meeting held in May in New York, New York. Psychiatric Times’ coverage included summaries of presentations, int…

Addressing the importance of safe treatments for PTSD, Dr John Miller discusses adverse effect management practices and the role of REMS protocols.

John J. Miller, MD, discusses how the diagnosis and treatment of posttraumatic stress disorder (PTSD) has evolved over time.

The Psychiatric Times editor-in-chief shares perspectives on how a novel treatment, MDMA-assisted therapy, can potentially change the treatment landscape and improve patients’ lives.

John J. Miller, MD, discusses the risks of untreated PTSD and the importance of implementing more therapeutic tools into treatment paradigms.

Are you attending Real Psychiatry in January?

Come celebrate the evolution of Psychiatric Times and psychiatry as a whole!

COVID-19 increased the usage of telemedicine drastically, but is that always a good thing?

Debate over using SSRIs in pregnancy in recent FDA focus group raises questions, despite extensive research supporting SSRI use for maternal mental health.